

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of **October 2022**

**Commission File Number 001-41231**

**TC BIOPHARM (HOLDINGS) PLC**

(Translation of registrant's name into English)

**Maxim 1, 2 Parklands Way  
Holytown, Motherwell, ML1 4WR  
Scotland, United Kingdom  
+44 (0) 141 433 7557**  
(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F

☐ Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): \_\_\_\_ ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): \_\_\_\_ ☐

---

---

---

***Notice, Proxy Statement and Proxy Card for Annual Shareholder Meeting***

TC BioPharm (Holdings) PLC (the “Company”) hereby publishes notice (“Notice”) of a general meeting of shareholders (the “Meeting”), which is scheduled to take place at 10:00 a.m. (UK time) on Tuesday, November 1, 2022, at the Company’s offices at Maxim 1, 2 Parklands Way, Holytown, Motherwell, ML1 4WR, Scotland, United Kingdom. The purpose of the Meeting is to carry out a proposed one for fifty consolidation of the ordinary share capital of the Company and to give effect to related matters which are described in the Notice.

Shareholders of record as of 10:00 a.m (UK time) on October 28, 2022 are entitled to vote at the Meeting. The Company’s holders of American Depositary Shares (the ADS Holders) are not shareholders of record, but, under the terms of the Depositary Agreement between the Company, the Depositary and the ADS Holders, they will be able to vote by proxy ahead of the meeting, before 12:00 p.m. Eastern Standard Time on October 25, 2022, in accordance with separate instructions which will be issued by the Depositary.

Attached as [Exhibit 99.1](#) to this Report of Foreign Private Issuer on Form 6-K (this “Form 6-K”) is the Notice of 2022 Meeting of Shareholders, which contains information concerning the agenda for the Meeting, background for the proposals at the Meeting, the voting procedure and additional general matters related to the Meeting.

Attached as [Exhibit 99.2](#) to this Form 6-K is the form of proxy card being distributed by the Company to its shareholders of record as of the record date for the Meeting, which serves as the primary means for those shareholders to cast their votes on the proposals to be presented at the Meeting.

Attached as [Exhibit 99.3](#) to this Form 6-K is the form of proxy card being distributed by the Depositary to ADS Holders of record as of September 28, 2022, which serves as the primary means for those ADS Holders to cast their votes on the proposals to be presented at the Meeting.

---

**Signature**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**TC BIOPHARM (HOLDINGS) PLC**

By: /s/ Martin Thorp

Name: Martin Thorp

Title: Chief Financial Officer

Date: October 6, 2022

---

**THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION.** If you are in any doubt about the contents of this document or as to what action you should take, you should consult your stockbroker, bank manager, solicitor, accountant or other independent financial adviser duly authorised under the Financial Services and Markets Act 2000 (as amended) if you are a resident of the United Kingdom or, if not, another appropriately authorised independent professional adviser.

---

**TC BioPharm (Holdings) plc**  
**(the “Company”)**

*(Incorporated and registered in Scotland with registered no: SC713098)*

**ONE FOR FIFTY SHARE CONSOLIDATION**

and

**NOTICE OF GENERAL MEETING**

---

This document should be read in its entirety. Your attention is drawn to the letter from Dr. Michael Leek, the Chairman of the Board of Directors of the Company, set out on pages 3 to 4 of this document.

---

## DIRECTORS, SECRETARY AND ADVISERS

### Directors

Dr Michael Leek  
Bryan Kobel  
Martin Thorp  
Dr Mark Bonyhadi  
James Culverwell  
Arlene Morris  
Edward Niemczyk

all of whose business address is at the Company's registered office.

### Registered Office

Maxim1, 2 Parklands Way  
Holytown  
Motherwell  
ML1 4WR  
United Kingdom

### Company website

[www.tcbiopharm.com](http://www.tcbiopharm.com)

### Company Secretary

Computershare Company Secretarial Services Limited

### Legal advisers to the Company

Addleshaw Goddard LLP  
Cornerstone, 107 West Regent Street  
Glasgow  
G2 2BA  
United Kingdom

Sheppard Mullin  
30 Rockefeller Plaza  
New York  
NY 10112  
United States of America

### Registrar

Computershare Investor Services PLC  
The Pavilions  
Bridgwater Road  
Bristol  
BS99 6ZY  
United Kingdom

### Depository

Bank of New York Mellon  
240 Greenwich Street  
New York  
NY 10286  
United States of America

---

## PROPOSED TIMETABLE

Publication and posting to Shareholders of this document	4 October 2022
Latest time and date for receipt of Forms of Proxy	10.00 a.m. on 28 October 2022
Record Date for voting on the Capital Reorganisation	10.00 a.m. on 28 October 2022
General Meeting (to be held at Maxim 1, 2 Parklands Way, Holytown, Motherwell, ML1 4WR, United Kingdom)	10.00 a.m. on 1 November 2022

### Notes:

1. Each of the above times and/or dates is subject to change at the absolute discretion of the Company.
2. If any of the above times and/or dates should change, the revised times and/or dates will be notified in writing.
3. All of the above times refer to London time unless otherwise stated.

## STATISTICS TABLE

Existing Ordinary Shares in issue at the date of this Document	39,747,729
Number of Existing Ordinary Shares expected to be in issue immediately prior to the Capital Reorganisation	39,747,750
Conversion ratio	1 New Ordinary Share for every 50 Existing Ordinary Share
Total expected number of New Ordinary Shares in issue following the Capital Reorganisation	794,955
ISIN code for the New Ordinary Shares	GB00BQD0NT81

---

## LETTER FROM THE CHAIRMAN

TC BioPharm (Holdings) plc  
(Incorporated in Scotland with registered number SC713098)

Dr Michael Leek  
Bryan Kobel  
Martin Thorp  
Dr Mark Bonyhadi  
James Culverwell  
Arlene Morris  
Edward Niemczyk

Maxim1, 2 Parklands Way  
Holytown  
Motherwell  
ML1 4WR  
United Kingdom

4 October 2022

Dear Shareholder

### Proposed One for Fifty Share Consolidation

and

### Notice of General Meeting

#### 1. Introduction

This document explains why the board of directors of the Company (“**Board**”) believes that it is in the best interests of shareholders of the Company (“**Shareholders**”) that the resolutions (“**Resolutions**”), which are described in the notice of general meeting set out in the end of this document (“**Notice**”), to carry out the proposed one for fifty consolidation of the ordinary share capital of the Company (“**Share Consolidation**”) and to give effect to related matters (“**Proposals**”), be approved by the shareholders of the Company (“**Shareholders**”).

The purpose of this document is to explain the background to the Proposals and to explain why the Board considers the proposed share consolidation to be in the best interests of the Company and the Shareholders as a whole and why the directors of the Company (“**Directors**”) recommend that you vote in favour of the Resolutions.

#### 2. Background to and reasons for the proposed Share Consolidation

At the date of this letter there are 39,747,729 ordinary shares of £0.01 each in the capital of the Company (“**Ordinary Shares**”) in issue. The closing price of the American Depositary Shares relating to the Company and issued by The Bank of New York Mellon (“**ADS**”) (each of which represents one ordinary share) on the Nasdaq Capital Market on the date prior to the date of this letter was \$0.2807.

The Directors consider that the number of existing ordinary shares in issue is unwieldy in volume for a company of our nature and, when combined with the prevailing share price, is not conducive to an orderly market.

The Board believes that the proposed **Share Consolidation** (on a **one for fifty** basis) of our ordinary share capital (which will be mirrored by a corresponding capitalization of underlying ADSs) will result in a more appropriate number of ADSs in issue for a company of our capitalization and should result in a more appropriate price per ADS and thereby help to make the Company more attractive to investors.

Further, we anticipate that the Share Consolidation will restore our compliance with the Continued Listing Standard of the Nasdaq Capital Markets, which requires us to maintain a share price of over \$1.00 per share.

In addition, the Company proposes to further undertake the sub-division of the new Ordinary Shares resulting from the Share Consolidation (described below), since, under the UK Company law, a UK company is prohibited from issuing new shares on terms that a shareholder will pay the company less than their nominal value and it is thought that the increased nominal value of the Ordinary Shares after the proposed Share Consolidation may restrict the strategic potential of the Company as may be appropriate from time to time.

---

### 3. Share Consolidation and Sub-division

The Share Consolidation comprises the consolidation of every 50 existing Ordinary Shares (with a nominal value of £0.01) into one new Consolidated Share (rounded down to the nearest whole share), with a nominal value of £0.50; and the subsequent sub-division of every such Consolidated Share into one new Ordinary Share with a nominal value of £0.0001 (“**New Ordinary Share**”) and one deferred share with a nominal value of £0.4999 (“**Sub-division**”) (“**Deferred Share**”).

To effect the Consolidation, it will be necessary to issue 21 additional Ordinary Shares (“**Additional Ordinary Shares**”) so that the Company’s issued ordinary share capital is exactly divisible by 50. These Additional Ordinary Shares would be issued to the Chief Financial Officer, Martin Thorp. Since these Additional Ordinary Shares would only represent an entitlement to a fraction of a new Ordinary Share of £0.50, this fraction would be disposed of after the Share Consolidation pursuant to the arrangements for fractional entitlements described below.

Following the issue of the Additional Ordinary Shares, the entire issued share capital will be consolidated into 794,955 Consolidated Shares of £0.50 each. Each such Consolidated Share will then be sub-divided into one New Ordinary Share and one Deferred Share.

Shareholders may hold at the Record Date a number of existing Ordinary Shares that is not exactly divisible by 50. The result of the Consolidation, if approved, will be that such Shareholders may be left with a fractional entitlement to a resulting Consolidated Share. Any such fractions will be aggregated and the Directors will, in accordance with the Articles, sell the aggregated shares and the proceeds from the sale of the fractional entitlements shall be distributed pro rata amongst the relevant Shareholders or retained by the Company at the discretion of the Board.

Most of our investors have dematerialized their Ordinary Shares into ADSs, which are listed on the Nasdaq Capital Markets, to enable trading in the Company’s securities. The Share Consolidation will be reflected on a one for one basis on the ADSs in issue and will be implemented by our depositary (Bank of New York Mellon) in line with the depositary agreement.

The rights attaching to the New Ordinary Shares will be identical in all respects to those of the Existing Ordinary Shares, including voting, dividend, return of capital and other rights.

The Deferred Shares shall, in effect, have no value, as described in Resolution 3, as (i) they will have no voting rights, (ii) no entitlement to distributions or dividends whatsoever, (iii) no rights to receive notice of or to attend or speak at a general meeting of shareholders, (iv) no entitlement to participation in the capital profits of assets of the Company, (v) in a return of capital on winding up they are only entitled to a return on capital after each New Ordinary Share receives repayment of its capital plus £100,000,000 per share, (vi) they will not be listed or traded on any stock market and (vii) the Company may at its discretion cancel the Deferred Shares or purchase them all for £0.01 in aggregate . The sole practical purpose of the issuance of the Deferred Shares is to facilitate the subdivision of the New Ordinary Shares in accordance with the Companies Act 2006.

### 4. General Meeting and action to be taken

You will find set out at the end of this document a notice convening a general meeting to be held at Maxim 1, 2 Parklands Way, Holytown, Motherwell, ML1 4WR, United Kingdom on 1 November 2022 at 10.00 a.m. together with a notice of proposed resolutions to give effect to the matters discussed herein.

### 5. Recommendation

The Board considers for the reasons set out above, that it is in the best interests of the Shareholders as a whole to pass each of the Resolutions. Accordingly, the Board unanimously recommends Shareholders to vote in favour of each of the Resolutions at the General Meeting. The Directors have stated their intention to vote in favour of all of the resolutions in respect of ordinary shares which they own.

Yours faithfully

Dr Michael Leek, Chairman

---

## NOTICE OF GENERAL MEETING OF SHAREHOLDERS

### TC BIOPHARM (HOLDINGS) PLC

Company No: SC713098

#### THE COMPANIES ACT 2006

#### RESOLUTIONS OF

#### TC BIOPHARM (HOLDINGS) PLC

**NOTICE IS HEREBY GIVEN** that a **GENERAL MEETING** of TC BioPharm (Holdings) plc (the “Company”) will be held as a physical meeting at Maxim 1, 2 Parklands Way, Holytown, Motherwell, ML1 4WR, United Kingdom on 1 November 2022 at 10.00 a.m. for the purpose of considering and, if thought fit, passing the following resolutions, which in the case of Resolutions 1 and 2 will be proposed as Ordinary Resolutions and in the case of Resolutions 3 and 4 will be proposed as Special Resolutions.

#### ORDINARY RESOLUTIONS

##### Resolution 1- Consolidation of Shares

THAT the 39,747,750 ordinary shares of £0.01 each in the capital of the Company in issue at 10.00 a.m. on 1 November 2022 be consolidated and divided into 794,955 ordinary shares of £0.50 each (**Consolidated Shares**) provided that, where such consolidation results in any shareholder being entitled to a fraction of a Consolidated Share, such fraction shall be dealt with by the directors as they see fit pursuant to the powers available to them under article 29 of the Company’s Articles of Association, as amended below (**Articles**).

##### Resolution 2 – Subdivision of shares and re-designation as Deferred Shares

THAT, subject to and conditional upon the passing of Resolutions 1, 3 and 4, each of the Consolidated Shares created by Resolution 1 be subdivided and reclassified into 1 ordinary share of £0.0001 and 1 deferred share of £0.4999 each in the capital of the Company (**Deferred Share**) such Deferred Shares to have the rights set out in the new article 7A referred to Resolution 3.

#### SPECIAL RESOLUTION

##### Resolution 3 - Amendment of Articles of Association

THAT, subject to and conditional upon the passing of Resolutions 1, 2 and 4, the Articles of Association of the Company be amended by the insertion of a new Article 7A immediately after Article 7, as follows:

“7A. Deferred Shares

The Deferred Shares of £ 0.4999 each in the capital of the Company (**Deferred Shares**) shall have the rights, and shall be subject to the restrictions, set out in this Article 7A (i) to (v) below (inclusive):

- (i) A Deferred Share:
    - a. does not entitle its holder to receive any dividend or other distribution;
    - b. does not entitle its holder to receive a share certificate in respect of the relevant shareholding;
    - c. does not entitle its holder to receive notice of, nor to attend, speak or vote at, any general meeting of the Company;
    - d. entitles its holder on a return of capital on a winding up of the Company (but not otherwise) only to the repayment of the amount paid up on that share after payment of the capital paid up on each Ordinary Share in the share capital of the Company and the further payment of £100,000,000 on each ordinary share;
    - e. does not entitle its holder to any further participation in the capital, profits or assets of the Company. The Deferred Shares shall not be capable of transfer at any time other than with the prior written consent of the directors of the Company.
-

- (ii) The Company may at its option and is irrevocably authorised at any time after the creation of the Deferred Shares to:
- a) appoint any person to act on behalf of any or all holder(s) of a Deferred Share(s), without obtaining the sanction of the holder(s), to transfer any or all of such shares held by such holder(s) for nil consideration to any person appointed by the directors of the Company;
  - b) without obtaining the sanction of the holder(s), but subject to the Companies Act 2006 and uncertificated securities rules:
    - 1) purchase any or all of the Deferred Shares then in issue and to appoint any person to act on behalf of all holders of Deferred Shares to transfer and to execute a contract of sale and a transfer of all the Deferred Shares to the Company for an aggregate consideration of one penny payable to one of the holders of Deferred Shares to be selected by lot (who shall not be required to account to the holders of the other Deferred Shares in respect of such consideration); and
    - 2) cancel any Deferred Share without making any payment to the holder.
- (iii) Any offer by the Company to purchase the Deferred Shares may be made by the Directors of the Company depositing at the registered office of the Company a notice addressed to such person as the Directors shall have nominated on behalf of the holders of the Deferred Shares.
- (iv) The rights attaching to the Deferred Shares shall not be, or be deemed to be, varied, abrogated, or altered by:
- a) the creation or issue of any shares ranking in pari passu with, the Deferred Shares;
  - b) the Company reducing its share capital or share premium account;
  - c) the cancellation of any Deferred Share without any payment to the holder thereof; or
  - d) the redemption or purchase of any share, whether a Deferred Share or otherwise, not by the passing by the member of the Company or any class of members of any resolution, whether in connection with any of the foregoing or for any other purpose, and accordingly no consent thereto or sanction thereof by the holders of the Deferred Shares, or any of them, shall be required.”

#### **Resolution 4 – Buy back of Deferred Shares**

THAT, subject to and conditional upon the passing of Resolutions 1, 2 and 3, the Company be authorised for the purposes of section 694 of the Companies Act 2006 to make one or more off market purchases (as defined in section 693(2) of the Companies Act 2006) of its Deferred Shares of £0.4999 each in accordance with the terms of the Articles of Association of the Company, as amended in accordance with resolution 3 above; such power to apply until 30 September 2027.

By order of the Board

Computershare Company Secretarial Services Limited  
Company Secretary

Registered Office  
Maxim 1  
2 Parklands Way  
Holytown  
Motherwell  
Scotland  
ML1 4WR

---

**Notes:**

1. Shareholders are entitled to appoint a proxy or (if a shareholder has more than one share) proxies to exercise all or any of that shareholder's their rights to attend, speak, and vote at the general meeting. A proxy need not be a shareholder of the Company. Please see the instructions on the enclosed Form of Proxy.
  2. Please indicate the proxy holder's name and the number of shares in relation to which they are authorised to act as your proxy (which, in aggregate, should not exceed the number of shares held by you) in the boxes indicated on the form. Please also indicate if the proxy instruction is one of multiple instructions being given. To appoint more than one proxy please see the instructions on the enclosed Form of Proxy. All forms must be signed and should be returned together in the same envelope.
  3. To be valid, the Form of Proxy and the power of attorney or other authority (if any) under which it is signed or a certified copy of such power or authority must be lodged at the offices of the Company's registrars, Computershare Investor Services PLC by hand, or sent by post, so as to be received not less than 48 hours excluding non-business days before the time fixed for the holding of the meeting or any adjournment thereof (as the case may be).
  4. A corporation which is a shareholder can appoint one or more corporate representatives who may exercise, on its behalf, all its powers as a shareholder provided that no more than one corporate representative exercises powers over the same share.
-

TC BioPharm (Holdings) plc



All Correspondence to:  
Computershare Investor Services PLC  
The Pavilions, Bridgwater Road,  
Bristol, BS99 6ZY

## Form of Proxy - General Meeting to be held on 1 November 2022

To be effective, all proxy appointments must be lodged with the Company's Registrars at:  
Computershare Investor Services PLC, The Pavilions, Bridgwater Road, Bristol BS99 6ZY by 28 October 2022 at 10.00 am.

### Explanatory Notes:

- Every holder has the right to appoint some other person(s) of their choice, who need not be a shareholder, as his proxy to exercise all or any of his rights, to attend, speak and vote on their behalf at the meeting. If you wish to appoint a person other than the Chairman, please insert the name of your chosen proxy holder in the space provided (see reverse). If the proxy is being appointed in relation to less than your full voting entitlement, please enter in the box next to the proxy holder's name (see reverse) the number of shares in relation to which they are authorised to act as your proxy. If returned without an indication as to how the proxy shall vote on any particular matter, the proxy will exercise his discretion as to whether, and if so how, he votes (or if this proxy form has been issued in respect of a designated account for a shareholder, the proxy will exercise his discretion as to whether, and if so how, he votes).
- To appoint more than one proxy, an additional proxy form(s) may be obtained by contacting the Registrar's helpline on 0370 703 6170 or you may photocopy this form. Please indicate in the box next to the proxy holder's name (see reverse) the number of shares in relation to which they are authorised to act as your proxy. Please also indicate by marking the box provided if the proxy instruction is one of multiple instructions being given. All forms must be signed and should be returned together in the same envelope.
- The 'Vote Withheld' option overleaf is provided to enable you to abstain on any particular resolution. However, it should be noted that a 'Vote Withheld' is not a vote in law and will not be counted in the calculation of the proportion of the votes 'For' and 'Against' a resolution.
- Pursuant to Regulation 41 of the Uncertificated Securities Regulations 2001, entitlement to attend and vote at the meeting and the number of votes which may be cast thereat will be determined by reference to the Register of Members of the Company at close of business on the day which is two days before the day of the meeting. Changes to entries on the Register of Members after that time shall be disregarded in determining the rights of any person to attend and vote at the meeting.
- The above is how your address appears on the Register of Members. If this information is incorrect please ring the Registrar's helpline on 0370 703 6170 to request a change of address form or go to [www.investorcentre.co.uk](http://www.investorcentre.co.uk) to use the online Investor Centre service.
- Any alterations made to this form should be initialled.
- The completion and return of this form will not preclude a member from attending the meeting and voting in person.

**Kindly Note:** This form is issued only to the addressee(s) and is specific to the unique designated account printed hereon. This personalised form is not transferable between different: (i) account holders; or (ii) uniquely designated accounts. The Company and Computershare Investor Services PLC accept no liability for any instruction that does not comply with these conditions.

All Named Holders

180082\_215886\_RUN\_ONS/000001/000001/SG601/i

## Form of Proxy

Please complete this box only if you wish to appoint a third party proxy other than the Chairman.  
Please leave this box blank if you want to select the Chairman. Do not insert your own name(s).

	*
--	---

I/We hereby appoint the Chairman of the Meeting OR the person indicated in the box above as my/our proxy to attend, speak and vote in respect of my/our full voting entitlement\* on my/our behalf at the General Meeting of TC BioPharm (Holdings) Plc to be held at **Maxim 1, 2 Parklands Way, Holytown, Motherwell, ML1 4WR, United Kingdom** on **1 November 2022** at **10.00 am**, and at any adjourned meeting.

\* For the appointment of more than one proxy, please refer to Explanatory Note 2 (see front).

☐ Please mark here to indicate that this proxy appointment is one of multiple appointments being made.

Please use a black pen. Mark with an X inside the box as shown in this example. ☒

### Ordinary Business

1. Consolidation of Shares

For	Against	Vote Withheld
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

2. Subdivision of shares and re-designation as Deferred Shares.

<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
--------------------------	--------------------------	--------------------------

### Special Business

3. Amendment of Articles of Association Buy back of Deferred Shares.

<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
--------------------------	--------------------------	--------------------------

4. Buy back of Deferred Shares

<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
--------------------------	--------------------------	--------------------------

I/We instruct my/our proxy as indicated on this form. Unless otherwise instructed the proxy may vote as he or she sees fit or abstain in relation to any business of the meeting.

Signature

--

Date

DD / MM / YY

In the case of a corporation, this proxy must be given under its common seal or be signed on its behalf by an attorney or officer duly authorised, stating their capacity (e.g. director, secretary).



H 7 1 7

0 1

T B P



General Meeting of  
TC Biopharm (Holdings) PLC

Date: Tuesday, November 1, 2022 at 10:00 a.m. G.M.T.  
See Voting Instruction On Reverse Side.

Please make your marks like this: ☒ Use pen only

The Board unanimously recommends holders to vote in favor of each of the Resolutions listed here.

ORDINARY RESOLUTIONS

Resolution 1 – Consolidation of Shares

Resolution 2 – Subdivision of shares and re-designation as Deferred Shares

SPECIAL RESOLUTION

Resolution 3 – Amendment of Articles of Association

Resolution 4 – Buy back of Deferred Shares

For

Against

Withhold

☐☐☐

☐☐☐


☐☐☐

☐☐☐

☐☐☐


↑ Please separate carefully at the perforation and return just this portion in the envelope provided. ↓

General Meeting of TC Biopharm (Holdings) PLC  
to be held on November 1, 2022  
for Holders as of September 28, 2022

 INTERNET


Go To  
[www.proxypush.com/TCBP](http://www.proxypush.com/TCBP)  
• Cast your vote online.  
• View Meeting Documents.

OR

 TELEPHONE

1-866-694-1495  
• Use any touch-tone telephone.  
• Have your Voting Instruction Form ready.  
• Follow the simple recorded instructions.

OR

 MAIL

• Mark, sign and date your Voting Instruction Form.  
• Detach your Voting Instruction Form.  
• Return your Voting Instruction Form in the  
postage-paid envelope provided.

All votes must be received by 12:00 p.m. Eastern Standard Time on October 25, 2022.

PROXY TABULATOR FOR  
TC BIOPHARM (HOLDINGS) PLC  
P.O. BOX 8016  
CARY, NC 27512-9903

EVENT #

CLIENT #

Authorized Signatures - This section must be completed for your instructions to be executed.

Please Sign Here

Please Date Above

Please Sign Here

Please Date Above

## TC Biopharm (Holdings) PLC

### Instructions to THE BANK OF NEW YORK MELLON, as Depositary (Must be received prior to 12:00 p.m. Eastern Standard Time on October 25, 2022)

The undersigned registered owner of American Depositary Receipts ("Receipts") hereby requests and instructs The Bank of New York Mellon, as Depositary, through its Agent, to endeavor, in so far as practicable, to vote or cause to be voted the Deposited Securities represented by such Receipt(s) of TC Biopharm (Holdings) PLC, registered in the name on the reverse side on the books of the Depositary as of 5:00 p.m. Eastern Standard Time on September 28, 2022, at the General Meeting of Ordinary Shareholders of TC Biopharm (Holdings) PLC to be held on November 1, 2022, in respect of the resolutions specified on the reverse hereof.

#### NOTES:

1. Instructions as to voting on the specified resolutions should be indicated by an "X" in the appropriate box.
2. The Depositary shall not vote or attempt to exercise the right to vote that attaches to the Shares of Deposited Securities other than in accordance with such instructions.

#### To the Registered Holders of American Depositary Receipts of TC Biopharm (Holdings) PLC

The General Meeting of TC Biopharm (Holdings) PLC will be held on Tuesday, November 1, 2022 at 10 a.m. G.M.T.

TC Biopharm (Holdings) PLC would like to inform you that the Notice of General Meeting and Shareholder Letter are available online at [www.tcbiopharm.com](http://www.tcbiopharm.com).

If you do not have access to the Internet and would like to obtain a hard copy of meeting material, please call toll free 1-800-555-2470, or write to:

Proxy Services Corporation  
10 Drew Court - Suite #3  
Ronkonkoma, NY 11779

If you wish to vote on-line or by phone, please follow the instructions listed on the other side of this voting card. If you wish to vote by using this voting card, please complete and return the duly marked and signed card in the envelope provided.

(Continued and to be marked, dated and signed, on the other side)

PROXY TABULATOR FOR  
TC BIOPHARM (HOLDINGS) PLC  
P.O. Box 8016  
CARY, NC 27512-9603